WHO Raises Warning Over Critical Lack of Obesity Jabs
Fewer than 10% of individuals that would benefit from weight-loss injections including Wegovy can access them, warns the global health agency as it issues its inaugural advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just availability to GLP-1 medication.
Based on projections, more than two billion are projected to be obese by 2030 without intervention.
"Our latest guidance acknowledges that obesity is a long-term condition that can be treated with thorough and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key obstacles to universal availability to the injections that can assist patients in reducing considerable body mass, notes the agency.
GLP-1 Therapy Supply Crisis
Despite the current best projected scenario, the supply of such drugs could only cover around 100 million people – less than 10% of those who need them, as stated by the WHO.
The guideline urges governments and firms to increase availability, via strategies like patent sharing.
Exclusive production rights on the active ingredient – the main component of a leading brand – is set to lapse in multiple countries in 2026.
The Way Obesity Jabs Work
These medications replicate a body's own hormone to delay gastric emptying, reduce hunger and enhance satiety so people reduce food intake.
Patients commonly start to lose weight after several weeks of beginning the weekly injections.
Studies suggests people may regain a significant portion after a year of stopping the drug, because their usual food cravings come back.
To be above a healthy weight increases your likelihood for developing health problems, like type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the WHO.
